Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at the Cantor 2026 Global Healthcare Conference, scheduled for September 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., is set to present on September 10 from 3:55-4:25 p.m. ET, with a live webcast and replay available through the Investors section of the Tonix website. This engagement provides a platform for Tonix to update the investment community on its commercial progress and clinical pipeline.
The company's flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), recently received approval and represents the first new treatment for fibromyalgia in over 15 years, addressing a significant unmet medical need. Tonix is leveraging its CNS commercial infrastructure to support TONMYA along with its acute migraine products, Zembrace® SymTouch® and Tosymra®. The company is also exploring TONMYA's potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder, which could expand its therapeutic indications and market opportunities.
Beyond CNS, Tonix maintains a robust immunology pipeline, including TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor aimed at preventing kidney transplant rejection. Additionally, TNX-2900 is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease with few therapeutic options. These programs highlight Tonix's commitment to addressing high unmet medical needs across multiple therapeutic areas.
The conference participation comes at a pivotal time as Tonix seeks to maximize TONMYA's commercial potential and advance its pipeline. With the fibromyalgia market underserved for over a decade, TONMYA's approval offers a new option for patients, and its ongoing clinical trials could provide further growth catalysts. Tonix's presence at the Cantor conference underscores its strategic focus on CNS and immunology, and its efforts to build value through both commercial execution and pipeline innovation.
Investors and industry observers will likely monitor the company's presentations for updates on TONMYA's launch metrics, clinical trial progress, and regulatory milestones. The live webcast and replay will provide broader access to management's insights, potentially influencing investor sentiment. As Tonix continues to navigate the complexities of biotech commercialization, its diversified portfolio and upcoming conference engagements are critical to communicating its long-term vision and operational achievements.
For more information about Tonix Pharmaceuticals and its recent announcements, visit the company's newsroom at https://nnw.fm/TNXP.
